Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

18,214 total articles

Parsons Expands Connected Vehicle Leadership, Delivering Statewide V2X Management System for the Utah Department of Transportation

Parsons Expands Connected Vehicle Leadership, Delivering Statewide V2X Management System for the Utah Department of Transportation

Parsons Corporation has been selected by the Utah Department of Transportation to develop, implement, and maintain a 10-year statewide Vehicle-to-Everything (V2X) Maintenance and Management System using its iNET® software. This contract expands Parsons' leadership in connected vehicle technologies and provides UDOT with real-time monitoring and ana…

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

Ascendis Pharma announced that its drug YUVIWEL (navepegritide) has been granted orphan drug exclusivity by the FDA and is now commercially available in the US. YUVIWEL is the first once-weekly FDA-approved treatment to increase linear growth in children with achondroplasia, providing continuous systemic exposure to CNP. Revenue generation has comm…

urban-gro, Inc. Outlines Strategy Targeting Global T20 Cricket Market and Near-Term Execution Milestones

urban-gro, Inc. Outlines Strategy Targeting Global T20 Cricket Market and Near-Term Execution Milestones

urban-gro, Inc. announces its strategic roadmap to enter and monetize the rapidly growing global T20 cricket ecosystem through its recent integration with Flash Sports & Media and Innovative Production Group. The company outlines near-term to long-term catalysts focused on market entry via player drafts, platform monetization, revenue scaling, and …

Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy

Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy

Sharps Technology transformed its financial position in 2025 by implementing a Solana-based digital asset treasury strategy, accumulating over 2 million SOL, achieving nearly $7 million in staking revenue, and significantly expanding its asset base, while phasing out unprofitable manufacturing operations to create a scalable, capital-efficient busi…

MidCap Financial Investment Corporation Schedules Earnings Release and Conference Call for Quarter Ended March 31, 2026

MidCap Financial Investment Corporation Schedules Earnings Release and Conference Call for Quarter Ended March 31, 2026

MidCap Financial Investment Corporation (NASDAQ: MFIC) has scheduled its earnings report for the quarter ended March 31, 2026, to be released after market close on May 6, 2026. The company will host a conference call on May 7, 2026, to discuss results. MidCap Financial is a diversified business development company primarily investing in first lien …

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

NRx Pharmaceuticals announced the FDA's preliminary alignment on the labeling for its preservative-free ketamine product under its generic drug application, with anticipated approval expected in Summer 2026. This product could help address current ketamine supply shortages in the U.S. and aligns with national priorities on domestic drug manufacturi…

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics, a clinical-stage biotech company specializing in gene therapies for inherited retinal diseases, announced a strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding to accelerate clinical development and potential commercialization of its gene therapy pipeline. The initial $35 million t…

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Agios Pharmaceuticals, a commercial-stage biopharmaceutical company focused on rare diseases, announced it will host a conference call and live webcast on April 29, 2026 to report its Q1 2026 financial results and business updates. The webcast will be accessible via the investor section of the company website, with a replay available shortly after …

Treasure Global Reappoints Former CEO Sam Teo as Acting CEO to Lead Next Phase of Growth; Carlson Thow to Continue as Executive Director

Treasure Global Reappoints Former CEO Sam Teo as Acting CEO to Lead Next Phase of Growth; Carlson Thow to Continue as Executive Director

Treasure Global Inc. reappoints Sam Teo as Acting CEO to lead the company's next growth phase, focusing on scaling its ZCITY platform, fintech, e-commerce, and emerging technology verticals. Carlson Thow steps down as CEO but remains as Executive Director to support strategic initiatives. The company reports strong user engagement and significant A…

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences announced presentations at the Fueling MASH Keystone Symposium detailing analysis from their Phase 2b FASCINATE-2 trial of denifanstat in MASH patients, showing significant reductions in bile acid biomarkers correlated with fibrosis and MASH resolution. Additionally, the company granted inducement options to a new employee under…

Exponent Elevates John Pye to President and Eric Anderson to CFO Reporting to Catherine Corrigan, CEO; Rich Schlenker to Remain as Executive VP and to Stand for Election to Board of Directors

Exponent Elevates John Pye to President and Eric Anderson to CFO Reporting to Catherine Corrigan, CEO; Rich Schlenker to Remain as Executive VP and to Stand for Election to Board of Directors

Exponent, Inc., a leading engineering and scientific consulting firm, announced key leadership changes effective May 1, 2026. John Pye is promoted to President, bringing extensive technical and leadership experience, while Eric Anderson is appointed CFO, leveraging his financial expertise and operational insight. Additionally, Richard Schlenker wil…